Screener
UroGen Pharma URGN Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The source filing: UroGen Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 8:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025794
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total current liabilities | 61,915 | 46,418 |
| Non-current liabilities: | ||
| Prepaid forward obligation | 125,135 | 127,276 |
| Long-term debt | 188,734 | 122,210 |
| Finance long-term lease liabilities | 2,939 | 3,475 |
| Operating long-term lease liabilities | 2,360 | 2,647 |
| Uncertain tax positions liability | 3,903 | 3,903 |
| Total liabilities | 384,986 | 305,929 |
Item 1. Financial Statements.
FAQ
- What is UroGen Pharma's long-term debt?
- UroGen Pharma (URGN) reported long-term debt of $188.73M in Q2 2026.
- How has UroGen Pharma's long-term debt changed year-over-year?
- UroGen Pharma's long-term debt increased by 54.1% year-over-year, from $122.51M to $188.73M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about UroGen Pharma's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude